Your browser is no longer supported. Please, upgrade your browser.
Settings
ALT Altimmune, Inc. daily Stock Chart
ALT [NASD]
Altimmune, Inc.
Index- P/E- EPS (ttm)-1.53 Insider Own10.00% Shs Outstand15.11M Perf Week114.49%
Market Cap406.77M Forward P/E- EPS next Y-1.92 Insider Trans143.06% Shs Float10.43M Perf Month269.42%
Income-22.30M PEG- EPS next Q-0.52 Inst Own30.50% Short Float18.50% Perf Quarter605.05%
Sales5.10M P/S79.76 EPS this Y89.50% Inst Trans428.16% Short Ratio0.47 Perf Half Y1095.19%
Book/sh2.77 P/B8.07 EPS next Y-6.10% ROA-39.40% Target Price13.00 Perf Year831.25%
Cash/sh1.81 P/C12.36 EPS next 5Y- ROE-46.20% 52W Range1.51 - 24.65 Perf YTD1082.54%
Dividend- P/FCF- EPS past 5Y50.20% ROI-47.00% 52W High-9.33% Beta1.69
Dividend %- Quick Ratio6.60 Sales past 5Y-10.70% Gross Margin- 52W Low1380.13% ATR2.47
Employees25 Current Ratio6.60 Sales Q/Q-26.70% Oper. Margin- RSI (14)89.25 Volatility37.42% 19.23%
OptionableYes Debt/Eq0.00 EPS Q/Q4.30% Profit Margin- Rel Volume4.32 Prev Close20.22
ShortableYes LT Debt/Eq0.00 EarningsMay 14 BMO Payout- Avg Volume4.11M Price22.35
Recom- SMA20127.18% SMA50206.69% SMA200542.65% Volume17,781,201 Change10.53%
Feb-24-20Resumed ROTH Capital Buy $13
Jul-19-19Initiated ROTH Capital Buy $8.30
Oct-09-17Initiated Piper Jaffray Overweight $6
Jul-09-20 11:30AM  
07:00AM  
Jul-08-20 08:04AM  
Jul-02-20 07:30PM  
Jun-30-20 07:00AM  
Jun-29-20 07:00AM  
Jun-22-20 07:00AM  
Jun-21-20 07:00AM  
Jun-17-20 08:45AM  
Jun-10-20 09:15AM  
Jun-09-20 09:15AM  
Jun-01-20 07:00AM  
May-28-20 11:34AM  
May-15-20 08:58AM  
May-13-20 05:18PM  
05:18PM  
09:15AM  
May-12-20 07:00AM  
May-09-20 08:11AM  
May-08-20 07:00AM  
May-06-20 02:50PM  
Apr-20-20 09:01AM  
Apr-13-20 08:58AM  
Apr-08-20 09:15AM  
Apr-02-20 02:51PM  
Mar-30-20 07:00AM  
Mar-27-20 07:15AM  
06:30AM  
Mar-25-20 04:30PM  
Feb-28-20 07:00AM  
Feb-19-20 04:30PM  
Feb-04-20 07:00AM  
Jan-31-20 04:58PM  
Jan-23-20 07:00AM  
Jan-07-20 08:43AM  
Dec-23-19 03:59PM  
Nov-21-19 08:00AM  
Nov-13-19 04:15PM  
Nov-11-19 05:43AM  
Nov-06-19 07:00AM  
Nov-01-19 02:41PM  
Oct-10-19 07:00AM  
Sep-09-19 07:00AM  
Aug-21-19 07:00AM  
Aug-13-19 04:15PM  
Aug-07-19 11:27AM  
Aug-05-19 07:00AM  
Jul-15-19 07:00AM  
Jul-12-19 02:55PM  
Jul-09-19 04:45PM  
01:39PM  
08:48AM  
07:15AM  
07:00AM  
Jun-12-19 08:00AM  
Jun-10-19 08:00AM  
Jun-05-19 08:00AM  
May-14-19 04:15PM  
May-08-19 08:00AM  
Apr-11-19 09:27AM  
Apr-02-19 06:30AM  
Apr-01-19 04:20PM  
Mar-21-19 04:15PM  
Mar-19-19 12:21PM  
08:12AM  
07:00AM  
Mar-14-19 09:00AM  
Mar-12-19 01:34PM  
Mar-08-19 09:29AM  
Jan-29-19 08:00AM  
Dec-14-18 07:00AM  
Dec-13-18 07:01AM  
Nov-30-18 06:06PM  
Nov-27-18 09:00AM  
Nov-23-18 07:00AM  
Nov-13-18 04:50PM  
Oct-26-18 11:29AM  
Oct-23-18 03:05PM  
Oct-17-18 08:00AM  
Oct-08-18 12:35PM  
09:00AM  
Oct-03-18 08:00AM  
Oct-01-18 08:00AM  
Sep-28-18 09:01AM  
Sep-24-18 09:00AM  
08:00AM  
Sep-20-18 08:00AM  
Sep-19-18 05:16PM  
Sep-04-18 08:00AM  
Aug-31-18 08:00AM  
Aug-15-18 06:30AM  
Aug-14-18 04:01PM  
Aug-07-18 08:00AM  
Jul-12-18 08:00AM  
Jul-10-18 08:00AM  
Jun-22-18 04:15PM  
Jun-11-18 07:10AM  
Jun-05-18 06:45AM  
May-24-18 01:47PM  
May-18-18 04:55PM  
Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Venrock Healthcare Capital Par10% OwnerJun 15Buy7.541,500,00011,310,0004,500,000Jun 15 03:23 PM
Venrock Healthcare Capital Par10% OwnerMay 28Buy8.72201,4741,757,0903,000,000May 28 06:34 PM
Venrock Healthcare Capital Par10% OwnerMay 27Buy7.71402,1623,098,7612,798,526May 28 06:34 PM
Venrock Healthcare Capital Par10% OwnerMay 26Buy9.34700,0006,539,6422,396,364May 28 06:34 PM
VELOCITY PHARMACEUTICAL HOLDIN10% OwnerMay 15Sale4.6530,622142,3921,687,250May 18 04:45 PM
VELOCITY PHARMACEUTICAL HOLDIN10% OwnerMay 14Sale4.81169,378814,7081,717,872May 18 04:45 PM
Garg Vipin KPresident and CEOSep 05Buy2.1020,00042,000342,907Sep 05 05:04 PM